The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial
Pharmacology, Toxicology and Pharmaceutical Science
4
6%
Neuroscience
4
6%
Unspecified
2
3%
Other
5
7%
Unknown
43
61%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 February 2023.
All research outputs
#15,665,271
of 23,275,636 outputs
Outputs from Clinical Research in Cardiology
#553
of 845 outputs
Outputs of similar age
#242,162
of 446,081 outputs
Outputs of similar age from Clinical Research in Cardiology
#16
of 21 outputs
Altmetric has tracked 23,275,636 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 845 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 31.2. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,081 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
